

It is important not to suddenly stop taking ruxolitinib as this can cause your MF-related symptoms to return, your spleen to enlarge and may make some patients very unwell.

.....
Contact no. of nurse or other:

.....
Name of nurse or other:

.....
Contact no. of prescriber:

.....
Name of prescriber:

Useful contacts

Medication Alert Card

JAKAVI® is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.

For patients with myelofibrosis (MF)
who have been prescribed

 **JAKAVI**®
ruxolitinib

**I am a patient on medication that
must not be stopped suddenly.**
**Keep this card in your wallet or handbag
so you have it whenever you need it.**



Very common
and common
side effects —

Haematological

- Thrombocytopenia
- Anaemia
- Neutropenia
- Pancytopenia

Non-haematological

- Unexpected bruising
- Dizziness
- Unexpected bleeding



Please talk to your doctor, pharmacist or nurse if you present with any of the above symptoms. Do not suddenly stop treatment

REPORTING OF SIDE EFFECTS: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.